This new formulation represents a significant improvement over protease inhibitor-containing paediatric ARV formulations that have been used in South Africa for decades.
First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
We have grown from $10 billion to $80 billion. India is not too far from reaching the league of top-10 countries in Biotech's global ecosystem”
The company has launched indigenously produced Dual Chamber Bags of global standards in India at a pocket-friendly price
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
Dr. Bernstein will tap into her decades of leadership and strategy experience as she transitions into this new role at APhA
Subscribe To Our Newsletter & Stay Updated
